Outset Medical 3Q 2026: Revenue $33.6M, Net loss $14.7M, EPS $(0.78) — 10-Q Summary

What happened

Outset Medical reported third-quarter 2026 revenue of $33.6 million, up 14% from a year earlier. Its net loss narrowed to $14.7 million from $17.8 million, and diluted loss per share improved to $0.78 from $1.00. Quarterly product and service revenue increased, while gross margin reached 40.7%.

Confirmed

Global impact / market context

Higher revenue and a narrower loss indicate improving quarterly results, while the stronger gross margin means the company retained more revenue after direct costs. Continued service growth could support recurring sales, but the reported loss shows Outset has not yet reached profitability.

Analyst inference

The quarter contrasts with weaker nine-month product revenue, which declined 1%, even as total nine-month revenue rose 3%. Investors may weigh whether quarterly console, consumable, and service growth can persist and improve financial results, rather than treating one quarter as a lasting trend.

Analyst inference

What to watch

1. Check later reports for revenue growth and whether net losses continue to narrow; sustained improvement would suggest sales gains are translating into better financial performance. Analyst inference
2. Track product revenue separately from service revenue: product sales rose in the quarter but fell over nine months, while service revenue increased in both periods. Confirmed
3. Watch whether broader adoption, greater use at existing sites, and expanded home dialysis support are followed by measurable growth in sales or service revenue. Proposed

Evidence

• Original source link unavailable